AZTA
$22.03
Azenta, Inc.
Intraday
Recent News
Azenta Buys UK Biocentre As Valuation Screens Cheap Despite Weak Momentum
Azenta (NasdaqGS:AZTA) announced the acquisition of UK Biocentre Limited. The deal is intended to expand Azenta’s biorepository capabilities. UK Biocentre Limited adds a UK based hub focused on large scale sample processing and storage. For investors following Azenta’s role in life sciences infrastructure, this move adds another piece to its biorepository platform. Azenta provides sample exploration and management solutions that support drug discovery, clinical research, and precision...
Has Azenta (AZTA) Fallen Too Far After Recent Share Price Weakness?
If you are wondering whether Azenta's share price now reflects good value or lingering risks, this article walks through what the numbers actually say about the stock. The shares last closed at US$21.42, and investors have seen returns of an 11.9% decline over 7 days, a 29.7% decline over 30 days, a 35.8% decline year to date, a 41.8% decline over 1 year and a 45.8% decline over 3 years, with a 75.0% decline over 5 years. These moves have put valuation front and center for many shareholders,...
Azenta Details UK Biocentre Buyout to Expand Europe Biobanking, Near-Term EBITDA Dilution Seen
Azenta (NASDAQ:AZTA) executives outlined the strategic and financial rationale for the company’s planned acquisition of UK Biocentre during a recorded conference call held Tuesday, March 10, 2026. Management said the deal is intended to expand Azenta’s European footprint, scale its biorepository ope
Tenet Healthcare, Revvity, Avantor, Azenta, and Elanco Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected contraction in employment, with the healthcare industry showing significant job losses.
Azenta Details Turnaround at Raymond James Conference, Targets Margin Gains and Recurring Revenue Growth
Azenta (NASDAQ:AZTA) executives used a presentation and fireside chat at the Raymond James Institutional Investor Conference to outline what CEO John Marotta described as a turnaround underway since he joined the company in September 2024, emphasizing portfolio focus, operational improvements, and a